Summit Therapeutics Inc [NASDAQ: SMMT] price surged by 19.59 percent to reach at $0.77.
The one-year SMMT stock forecast points to a potential upside of 41.25. The average equity rating for SMMT stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Summit Therapeutics Inc [SMMT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SMMT shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SMMT stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Summit Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 26, 2024. The new note on the price target was released on June 28, 2018, representing the official price target for Summit Therapeutics Inc stock. On April 12, 2018, analysts decreased their price target for SMMT shares from 30 to 27.
The Average True Range (ATR) for Summit Therapeutics Inc is set at 0.35 The Price to Book ratio for the last quarter was 42.45, with the Price to Cash per share for the same quarter was set at 0.27.
SMMT Stock Performance Analysis:
Summit Therapeutics Inc [SMMT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.92. With this latest performance, SMMT shares gained by 22.08% in over the last four-week period, additionally plugging by 144.16% over the last 6 months – not to mention a rise of 215.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SMMT stock in for the last two-week period is set at 67.31, with the RSI for the last a single of trading hit 77.30, and the three-weeks RSI is set at 61.57 for Summit Therapeutics Inc [SMMT]. The present Moving Average for the last 50 days of trading for this stock 4.05, while it was recorded at 3.98 for the last single week of trading, and 2.79 for the last 200 days.
Insight into Summit Therapeutics Inc Fundamentals:
Summit Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.
Summit Therapeutics Inc [SMMT] Institutonal Ownership Details
The top three institutional holders of SMMT stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in SMMT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in SMMT stock with ownership which is approximately 5.8386%.
